Furthermore, regardless of their primary metabolic dependency, rotenone combined with venetoclax (VEN, a BCL2 inhibitor) showed strong synergistic effects in all tested AML models, which was validated in an ex vivo drug screen using primary AML cells (Supplementary Fig. 3d). The gene discussed is BCL2; the disease is acute myeloid leukemia.